NextFin News - The U.S. Food and Drug Administration (FDA) purged its top drug and biologics leadership late Friday, marking the most aggressive restructuring of the agency’s scientific core since U.S. President Trump took office. According to an internal memo seen by CNBC, the acting directors of the two most powerful divisions within the agency—the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER)—have been removed from their posts effective immediately.
The departures of Tracy Beth Høeg at CDER and Katherine Szarama at CBER follow the resignation of FDA Commissioner Marty Makary earlier this week. While Szarama is expected to remain at the agency in a different capacity, Høeg stated publicly on social media that she was fired. The rapid-fire turnover has installed Karim Mikhail as the new acting head of CDER and Michael Davis at CBER, making Davis the fifth person to lead the drug evaluation division in just sixteen months. Lowell Zeta, a former FDA senior advisor, has been named acting chief of staff to stabilize the agency’s internal operations.
This administrative vacuum comes at a delicate moment for the pharmaceutical industry. The Nasdaq Biotechnology Index (NBI) reflected the mounting uncertainty on Friday, closing at 5,946.08, a decline of approximately 1.7% from the previous day’s session as investors weighed the implications of a leaderless regulatory body. The FDA oversees products accounting for roughly 20% of all U.S. consumer spending, and the lack of permanent, Senate-confirmed leadership in its primary review divisions threatens to slow the approval pipeline for new therapies and vaccines.
The instability is viewed by some as a deliberate effort by the Trump administration to break down what it has characterized as "regulatory capture" within the federal health bureaucracy. However, the frequency of leadership changes has sparked concern among industry advocates. Georgia Life Sciences, a regional trade group, issued a statement urging the administration to maintain "continuity across review divisions" to ensure that decisions remain grounded in scientific standards rather than political shifts. The group’s plea highlights a growing anxiety that the "predictability" required for multi-billion dollar drug development cycles is evaporating.
Market sentiment remains divided on the long-term impact of the shakeup. Some analysts suggest that the removal of Makary and his deputies could pave the way for a more "industry-friendly" commissioner who might accelerate approvals. Conversely, the current "acting" status of nearly every major leadership role creates a bottleneck. Without Senate-confirmed directors, the agency often lacks the political capital to make high-stakes decisions on controversial drugs or to finalize complex guidance documents that the industry relies upon for R&D planning.
The White House has indicated it intends to name a permanent nominee for FDA Commissioner within weeks. Until then, the agency remains in a state of flux, with its organizational chart being updated in real-time to reflect a revolving door of interim officials. The immediate challenge for Mikhail and Davis will be to reassure the thousands of career scientists within the FDA that the agency’s mission remains intact, even as its upper echelons are rebuilt from the ground up.
Explore more exclusive insights at nextfin.ai.
